Identifying Risks for Dysplastic or Neoplastic Progression in Barrett Esophagus

A meta-analysis confirms some previously identified predictors of progression that might assist in determining appropriate surveillance.

The risk for esophageal adenocarcinoma (EAC) in patients with Barrett esophagus (BE) appears to be relatively modest, challenging the cost-effectiveness of current screening recommendations. Maximizing resource utilization might be helped by limiting surveillance to high-risk patients. Risk factors for progression (length of BE, presence of dysplasia, hiatal hernia >3 cm, increasing age, obesity, smoking, and male gender) have been identified in some studies but not in others (NEJM JW Gastroenterol May 2017 and Clin Gastroenterol Hepatol 2017; 15:950).

To further investigate predictors of progression in BE, researchers conducted a systematic review and meta-analysis of data from 20 cohort studies comprising approximately 75,000 patients with…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors